The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 801–900 of 1,006
Cascella, B., & Mirica, L. M. (2012) · Biochemistry · doi:10.1021/bi3012466 · Cited by 62
Lombardi, G., Corona, G., Bellu, L., Puppa, A. D., Pambuku, A., Fiduccia, P., Bertorelle, R., Gardiman, M. P., D’Avella, D., Toffoli, G., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0266 · Cited by 61
Recent advances in cancer metabolism: a technological perspective
Kang, Y. P., Ward, N. P., & DeNicola, G. M. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0027-z · Cited by 65
Nazari, P. M. S., Riedl, J., Preusser, M., Posch, F., Thaler, J., Marosi, C., Birner, P., Ricken, G., Hainfellner, J. A., Pabinger, I., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14129 · Cited by 63
Correlation between IDH, ATRX, and TERT promoter mutations in glioma
Ohba, S., Kuwahara, K., Yamada, S., Abe, M., & Hirose, Y. (2020) · Brain Tumor Pathology · doi:10.1007/s10014-020-00360-4 · Cited by 66
Signaling circuitries controlling stem cell fate: to be or not to be
Iglesias‐Bartolomé, R., & Gutkind, J. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.08.002 · Cited by 63
Mitochondrial acetyl-CoA reversibly regulates locus-specific histone acetylation and gene expression
Lozoya, O. A., Wang, T., Grenet, D., Wolfgang, T. C., Sobhany, M., da Silva, D. G., Riadi, G., Chandel, N. S., Woychik, R. P., & Santos, J. H. (2019) · Life Science Alliance · doi:10.26508/lsa.201800228 · Cited by 63
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
Self-citationTesileanu, C. M. S., Vallentgoed, W. R., Sanson, M., Taal, W., Clement, P. M., Wick, W., Brandes, A. A., Baurain, J. F., Chinot, O. L., Wheeler, H., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02291-6 · Cited by 62
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., & Illig, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11759 · Cited by 64
Xiao, D., Huang, J. X., Pan, Y., Li, H. R., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., et al. (2016) · Theranostics · doi:10.7150/thno.17032 · Cited by 62
Self-citationThe Molecular Genetics of Myeloproliferative NeoplasmsPreprint
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 65
Targeting the epigenome in in-stent restenosis: from mechanisms to therapy
Yang, X., Yang, Y., Guo, J., Meng, Y., Li, M., Yang, P., Liu, X., Aung, L. H. H., Yu, T., & Li, Y. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.024 · Cited by 60
Self-citationGriffioen, M. S., de Leeuw, D. D., Janssen, J., & Smit, L. (2022) · Cancers · doi:10.3390/cancers14143456 · Cited by 60
Current concepts in organic acidurias: understanding intra‐ and extracerebral disease manifestation
Kölker, S., Burgard, P., Sauer, S. W., & Okun, J. G. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9600-8 · Cited by 62
A metabolic signature for long life in the C aenorhabditis elegans M it mutants
Butler, J. A., Mishur, R. J., Bhaskaran, S., & Rea, S. L. (2012) · Aging Cell · doi:10.1111/acel.12029 · Cited by 64
Liu, Z., Yao, Y., Kogiso, M., Zheng, B., Deng, L., Qiu, J. J., Dong, S., Lv, H., Gallo, J. M., Li, X., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500660f · Cited by 60
The Crabtree and Warburg effects: Do metabolite-induced regulations participate in their induction?
Hammad, N., Rosas‐Lemus, M., Uribe‐Carvajal, S., Rigoulet, M., & Devin, A. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.03.034 · Cited by 61
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases
Zurlo, G., Guo, J., Takada, M., Wei, W., & Zhang, Q. H. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.004 · Cited by 62
Molecular pathology of paediatric central nervous system tumours
Chiang, J., & Ellison, D. W. (2016) · The Journal of Pathology · doi:10.1002/path.4813 · Cited by 63
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Williams, M. J., Singleton, W., Lowis, S. P., Malik, K. T. A., & Kurian, K. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00045 · Cited by 62
Sasine, J. P., & Schiller, G. J. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.07.002 · Cited by 58
Crump, N. T., Hadjinicolaou, A. V., Meng, X., Walsby-Tickle, J., Gileadi, U., Chen, J., Setshedi, M., Olsen, L. R., Lau, I., Godfrey, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109101 · Cited by 61
Grilo, L. F., Tocantins, C., Diniz, M. S., Gomes, R. M., Oliveira, P. J., Matafome, P. N., & Pereira, S. P. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13625 · Cited by 67
SPOP mutation induces DNA methylation via stabilizing GLP/G9a
Zhang, J., Gao, K., Xie, H., Wang, D., Zhang, P., Wei, T., Yan, Y., Pan, Y., Ye, W., Chen, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25951-3 · Cited by 62
Self-citationWang, X., Chen, Z., Xu, J., Tang, S., An, N., Jiang, L., Zhang, Y., Zhang, S., Zhang, Q., Shen, Y., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00650-w · Cited by 60
Self-citationThe role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Dalle, I. A., & Dinardo, C. D. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718777467 · Cited by 60
The small members of the JMJD protein family: Enzymatic jewels or jinxes?
Oh, S., Shin, S., & Janknecht, R. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.002 · Cited by 60
Acute Myeloid Leukemia: Aging and Epigenetics
Zjablovskaja, P., & Florian, M. C. (2019) · Cancers · doi:10.3390/cancers12010103 · Cited by 61
Rethinking the biology of metastatic melanoma: a holistic approach
Vandyck, H. H., Hillen, L. M., Bosisio, F. M., van den Oord, J., Hausen, A. Z., & Winnepenninckx, V. J. L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09960-8 · Cited by 65
Wu, H., Tong, H., Du, X., Guo, H., Ma, Q., Zhang, Y., Zhou, X., Liu, H., Wang, S., Fang, J., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06702-2 · Cited by 59
Self-citationDynamic metabolism during early mammalian embryogenesis
Zhao, J., Wang, W., Zhang, L., Zhang, J. Y., Sturmey, R. G., & Zhang, J. (2023) · Development · doi:10.1242/dev.202148 · Cited by 65
Self-citationMolecular markers of glioma: an update on recent progress and perspectives
Gupta, K., & Salunke, P. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1323-y · Cited by 60
Venneti, S., Felicella, M. M., Coyne, T. M., Phillips, J. J., Gorovets, D. J., Huse, J. T., Kofler, J., Lü, C., Tihan, T., Sullivan, L. M., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182898113 · Cited by 61
Matteo, D. A., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A. D., & Sohl, C. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776179 · Cited by 62
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 57
Unravelling the role of epigenetics in reproductive adaptations to early-life environment
Bar-Sadeh, B., Rudnizky, S., Pnueli, L., Bentley, G. R., Stöger, R. J., Kaplan, A., & Melamed, P. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0370-8 · Cited by 61
Ogawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 60
Epigenetic alterations in hematopoietic malignancies
Chung, Y. R., Schatoff, E. M., & Abdel-Wahab, O. I. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1181-z · Cited by 59
Metabolomics of colorectal cancer: past and current analytical platforms
Williams, M. D., Reeves, R., Resar, L. M. S., & Hill, H. H. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6777-5 · Cited by 58
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Genetics of Myeloproliferative Neoplasms
Viny, A. D., & Levine, R. L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000013 · Cited by 60
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Cuyàs, E., Fernández‐Arroyo, S., Corominas-Faja, B., Rodríguez‐Gallego, E., Bosch‐Barrera, J., Martı́n-Castillo, B., Llorens, R., Joven, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3733 · Cited by 60
Navis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
IDH1/2 mutation detection in gliomas
Arita, H., Narita, Y., Yoshida, A., Hashimoto, N., Yoshimine, T., & Ichimura, K. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0197-x · Cited by 58
Liu, S., Jiang, J., Li, L., Amato, N. J., Wang, Z., & Wang, Y. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b03386 · Cited by 58
Murray, D. H., Symonds, E. L., Young, G. P., Byrne, S. E., Rabbitt, P., Roy, A. C., Cornthwaite, K. J., Karapetis, C. S., & Pedersen, S. K. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2701-x · Cited by 58
Chen, Y.-C., Gotea, V., Margolin, G., & Elnitski, L. L. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005840 · Cited by 56
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 59
TET2: A cornerstone in normal and malignant hematopoiesis
Kunimoto, H., & Nakajima, H. (2020) · Cancer Science · doi:10.1111/cas.14688 · Cited by 56
Mitochondria orchestrate macrophage effector functions in atherosclerosis
Dumont, A., Lee, M., Barouillet, T., Murphy, A. J., & Yvan‐Charvet, L. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100922 · Cited by 60
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma
Reuss, A. M., Groos, D., Buchfelder, M., & Savaskan, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115518 · Cited by 58
Molecular and Circulating Biomarkers in Patients with Glioblastoma
Senhaji, N., Houssaini, A. S., Lamrabet, S., Louati, S., & Bennis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137474 · Cited by 60
Functions and Interactions of Mammalian KDM5 Demethylases
Pavlenko, E. A., Ruengeler, T., Engel, P., & Poepsel, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.906662 · Cited by 60
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 62
5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State
Laird, A., Thomson, J. P., Harrison, D. J., & Meehan, R. R. (2013) · Epigenomics · doi:10.2217/epi.13.69 · Cited by 58
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Le, A., Rajeshkumar, N. V., Maitra, A., & Dang, C. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0041 · Cited by 57
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 63
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma
Agnihotri, S., Aldape, K., & Zadeh, G. M. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14505 · Cited by 59
EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma
Tanner, J. M., Bensard, C., Wei, P., Krah, N. M., Schell, J. C., Gardiner, J. D., Schiffman, J. D., Lessnick, S. L., & Rutter, J. P. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0182 · Cited by 61
Epigenetics in myelodysplastic syndromes
Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61
Ye, C., Sutter, B. M., Wang, Y., Kuang, Z., Zhao, X., Yu, Y., & Tu, B. P. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.012 · Cited by 56
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
Ruiz‐Rodado, V., Malta, T. M., Seki, T., Lita, A., Dowdy, T., Celiku, O., Saldana, A. C., Li, A., Liu, Y., Han, S., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz207 · Cited by 58
Self-citationMetabolic Control of m6A RNA Modification
Kim, J., & Lee, G. (2021) · Metabolites · doi:10.3390/metabo11020080 · Cited by 57
Jia, J., Shi, Y., Chen, L., Lai, W., Yan, B., Jiang, Y., Xiao, D., Xi, S., Cao, Y., Liu, S., et al. (2017) · Theranostics · doi:10.7150/thno.21389 · Cited by 57
Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases
Yang, G., Xia, Y., & Ren, W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1703-2 · Cited by 55
Metabolism navigates neural cell fate in development, aging and neurodegeneration
Traxler, L., Lagerwall, J., Eichhorner, S., Stefanoni, D., D’Alessandro, A., & Mertens, J. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048993 · Cited by 59
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch
Wang, H., Hu, D., Cheng, Y., Gao, Q., Liu, K., Mani, N. L., Tang, A. Y., Iyer, R., Gao, B., Sun, L., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02166-y · Cited by 59
Self-citationMetabolic Modulation of Epigenetics in Gliomas
Venneti, S., & Thompson, C. B. (2013) · Brain Pathology · doi:10.1111/bpa.12022 · Cited by 56
Ma, S., Jiang, B., Deng, W., Gu, Z.-K., Wu, F.-Z., Li, T., Xia, Y., Yang, H., Ye, D., Xiong, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3330 · Cited by 57
Self-citationHitchler, M. J., & Domann, F. E. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.028 · Cited by 56
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 62
Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 56
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 55
Epigenetic determinants of metastasis
Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 58
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
Harvey, L. D., & Chan, S. Y. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040043 · Cited by 59
The metabolic axis of macrophage and immune cell polarization
Hobson-Gutierrez, S., & Carmona‐Fontaine, C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034462 · Cited by 57
Decoding the Rosetta stone of mitonuclear communication
English, J., Son, J. M., Cardamone, M. D., Lee, C., & Perissi, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105161 · Cited by 55
Pirro, V., Seró, R., Jarmusch, A. K., Alfaro, C. M., Cohen‐Gadol, A., Hattab, E. M., & Cooks, R. G. (2017) · The Analyst · doi:10.1039/c7an01334e · Cited by 55
Williams, N. C., Ryan, D. G., Costa, A. S. H., Mills, E. L., Jedrychowski, M. P., Cloonan, S. M., Frezza, C., & O'Neill, L. A. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101501 · Cited by 57
Drumm, M. R., Wang, W., Sears, T. K., Burdett, K. B., Javier, R., Cotton, K. Y., Webb, B., Byrne, K., Unruh, D. J., Thirunavu, V. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168035 · Cited by 58
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 57
Metabolic circuits in neural stem cells
Kim, D., Rhee, I., & Paik, J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1686-0 · Cited by 59
Valentini, E., Zampieri, M., Malavolta, M., Bacalini, M. G., Calabrese, R., Guastafierro, T., Reale, A., Franceschi, C., Hervonen, A., Koller, B., et al. (2016) · Aging · doi:10.18632/aging.101022 · Cited by 56
Viswanath, P., Radoul, M., Izquierdo-García, J. L., Ong, W. Q., Luchman, H. A., Cairncross, J. G., Huang, B., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2926 · Cited by 54
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
Peterse, E. F. P., Niessen, B., Addie, R. D., de Jong, Y., Cleven, A. H. G., Kruisselbrink, A. B., van den Akker, B. E. W. M., Molenaar, R. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0050-9 · Cited by 55
Liu, X., Wang, X., Du, W., Chen, L., Wang, G., Cui, Y., Liu, Y., Dou, Z., Wang, H., Zhang, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2585 · Cited by 54
Self-citationAntagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 54
Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification
Olar, A., & Sulman, E. P. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.006 · Cited by 56
5-Hydroxymethylcytosine and disease
Wang, J., Tang, J., Lai, M., & Zhang, H. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.09.003 · Cited by 54
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 54
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
Garbarino, J. M., Eckroate, J., Sundaram, R. K., Jensen, R. B., & Bindra, R. S. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101147 · Cited by 54
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
